Zoetis

Zoetis's reported carbon emissions

Zoetis, a Pharmaceutical Preparation Manufacturing company headquartered in the US, is committed to reducing its environmental impact. For the reporting year 2025, Zoetis reported total global emissions of approximately 149,380,000 kg CO2e, encompassing Scope 1 and Scope 2 emissions. Scope 1 emissions were approximately 122,311,000 kg CO2e, with Scope 2 market-based emissions at approximately 27,069,000 kg CO2e. Scope 3 emissions for business travel and employee commute were approximately 24,126,000 kg CO2e and 13,529,000 kg CO2e, respectively. In 2024, the company's total Scope 1 and 2 emissions were approximately 137,739,000 kg CO2e. Scope 1 emissions were approximately 107,033,000 kg CO2e and Scope 2 market-based emissions were approximately 30,707,000 kg CO2e. Scope 3 emissions for business travel and employee commute were approximately 24,620,000 kg CO2e and 13,825,000 kg CO2e. For 2023, Zoetis reported total Scope 1 and 2 emissions of approximately 185,086,000 kg CO2e. Scope 1 emissions were approximately 105,549,000 kg CO2e and Scope 2 market-based emissions were approximately 79,537,000 kg CO2e. Scope 3 emissions for business travel and employee commute were approximately 21,367,000 kg CO2e and 13,556,000 kg CO2e. Zoetis has set ambitious targets to achieve carbon neutrality in its own operations by 2030, with a specific focus on Scope 1 and Scope 2 emissions from manufacturing, R&D operations, office locations, and fleet vehicles. They aim for an 18.9% reduction in Scope 1 and 2 emissions as part of this near-term goal. Additionally, Zoetis is working to reduce energy intensity in manufacturing and R&D by 5% by 2025, using a 2019 baseline. This target applies to both Scope 1 and Scope 2 emissions. The company's climate commitments are not cascaded from a parent organisation.